Aurinia Pharmaceuticals — Q3 2026 Earnings Summary

Financial Performance:

• Total revenue for the three months ended September 30, 2026, was $83.7 million, a 14% increase from $73.5 million in the same period of 2025; for the nine months ended September 30, 2026, total revenue was $244.6 million, a 19% increase from $205.9 million in 2025.
• Net product sales of LUPKYNIS were $79.4 million for the three months ended September 30, 2026 (up 12% from $70.6 million in 2025) and $232.4 million for the nine months ended September 30, 2026 (up 18% from $197.2 million in 2025).
• License, collaboration, and royalty revenue was $4.3 million for the three months ended September 30, 2026 (up 54% from $2.8 million in 2025) and $12.2 million for the nine months ended September 30, 2026 (up 39% from $8.8 million in 2025).
• Net income before taxes was $38.7 million for the three months ended September 30, 2026 (up 21% from $32.0 million in 2025) and $131.4 million for the nine months ended September 30, 2026 (up 67% from $78.5 million in 2025).
• Net income was $31.7 million for the three months ended September 30, 2026 (flat compared to $31.6 million in 2025) and $103.5 million for the nine months ended September 30, 2026 (up 35% from $76.4 million in 2025).
• Diluted earnings per share was $0.23 for the three months ended September 30, 2026 (flat from $0.23 in 2025) and $0.76 for the nine months ended September 30, 2026 (up 38% from $0.55 in 2025).
• Cash flows from operating activities were $46.4 million for the three months ended September 30, 2026 (up 4% from $44.5 million in 2025) and $131.5 million for the nine months ended September 30, 2026 (up 46% from $90.0 million in 2025).
• As of September 30, 2026, total assets were $825.7 million compared to $751.6 million as of December 31, 2025; total liabilities were $168.2 million compared to $170.3 million at year-end 2025.
• Deferred revenue increased to $17.6 million ($10.4 million current, $7.2 million non-current) as of September 30, 2026, from $16.4 million ($3.7 million current, $12.6 million non-current) as of December 31, 2025.

Guidance and Future Outlook:

• Aurinia increased its 2026 total revenue guidance from a range of $315 million to $325 million to a range of $325 million to $330 million.
• Aurinia narrowed its 2026 net product sales guidance from a range of $305 million to $315 million to a range of $310 million to $315 million.

Business Segments and Product Lines:

• LUPKYNIS, the first FDA-approved oral therapy for adult patients with active lupus nephritis, remains the primary revenue driver.
• Aurinia initiated the PRESERVE Phase 4 multicenter study to investigate the combination of LUPKYNIS with belimumab, obinutuzumab, or anifrolumab in patients with lupus nephritis.
• The PRESERVE study plans to enroll approximately 150 patients across approximately 50 sites in the US, with a primary endpoint of complete renal response (CRR) at 6 months.
• Clinical development of aritinercept, a dual inhibitor of BAFF and APRIL for autoimmune diseases, has been initiated in four potential indications.

Other Key Points:

• Cash, cash equivalents, restricted cash, and investments totaled $486.9 million as of September 30, 2026, compared to $398.0 million at December 31, 2025.
• For the nine months ended September 30, 2026, cash outflows from financing activities were $53.2 million, primarily driven by the repurchase of 5.0 million common shares for $74.9 million.
• Financing activities were partially offset by proceeds from the issuance of common shares for equity awards, net of tax withholding payments, of $35.9 million.
• The company reported a net decrease in cash, cash equivalents, and restricted cash of $34.1 million for the nine months ended September 30, 2026.
• Forward-looking statements in the release caution that actual outcomes may differ materially due to risks associated with LUPKYNIS sales, clinical study timing, and other uncertainties identified in SEC filings.